Jasper Therapeutics Launches Tender Offer to Buy Back Warrants
Jasper Therapeutics is offering $0.324 per warrant to retire all outstanding warrants issued in its September 2025 public offering, aiming to limit shareholder dilution.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) announced Wednesday it has commenced a tender offer to purchase all outstanding warrants tied to its common stock, moving to clean up its capital structure ahead of anticipated milestones for the Redwood City, California-based clinical-stage biotech.
The company is offering holders $0.324 in cash per warrant, with no interest attached. The warrants targeted in the offer were originally issued during Jasper's underwritten public offering on September 18, 2025. Any warrants successfully tendered will be retired and permanently cancelled, removing them from the company's capitalization table.
Read more JLL Income Property Trust Secures $68.5M Indianapolis Industrial Loan →
Jasper stated the primary rationale is reducing the potential dilutive effect those warrants would otherwise have on existing shareholders if exercised for shares of common stock, which carries a par value of $0.0001 per share. By eliminating the instruments outright, the company aims to give current shareholders and prospective investors clearer visibility into the company's equity structure going forward.
The move is a common capital management strategy among development-stage biotechnology firms, which frequently issue warrants as sweeteners in public offerings to attract investors. Buying back those instruments at a discount to theoretical exercise value can reduce overhang on a company's stock while signaling management confidence in the underlying share price.
Continue reading at GlobeNewswire - Industry News on Financial Services.
